N/A
N=175
Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds
Nasolabial Folds in Chinese Population
Bottom Line
View on ClinicalTrials.gov: NCT03003130 ↗Enrolled (actual)
175
Serious AEs
1.7%
Results posted
Jun 2021
Primary outcome: Primary: Percentage of Responders, Defined by at Least 1-point Improvement From Baseline on the WSRS. — 72.9; 72.8 percentage of subjects
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Restylane Defyne (Device); Restylane (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Galderma R&D
- Primary completion
- Mar 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Responders, Defined by at Least 1-point Improvement From Baseline on the WSRS. |
72.9; 72.8 | — |
Summary
This is a randomized, split face, multicenter study to evaluate the efficacy and safety of Restylane Defyne compared to Restylane in correction of NLFs.
Eligibility Criteria
Inclusion Criteria
- Signed informed consent.
- Men or women aged 18 years of age or older of Chinese origin.
- Subjects willing to abstain from any other facial plastic surgical or cosmetic procedures below the level of the lower orbital rim for the duration of the study.
- Intent to undergo correction of both NLFs with a wrinkle severity in WSRS of either 3 on both sides or 4 on both sides, as assessed by the blinded evaluator.
Exclusion Criteria
- Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) Gel and/or local anesthetics, e.g., lidocaine or other amide-type anesthetics.
- Previous tissue revitalization treatment below the level of the lower orbital rim within 6 months before treatment.
- Previous surgery or tattoo in the area to be treated.
- Previous tissue augmentation therapy or contouring with any permanent (nonbiodegradable) or semi-permanent facial tissue augmentation therapy or autologous fat or permanent implant below the level of the lower orbital rim.
- Previous use of neurotoxins or any hyaluronic acid based or collagen based biodegradable facial tissue augmentation therapy below the level of the lower orbital rim within 12 months before treatment.
- Scars or deformities, active skin disease, inflammation or related conditions such as infection, perioral dermatitis, seborrheic dermatitis, eczema, rosacea, acne, psoriasis, and herpes zoster near or in the area to be treated.
- Other condition preventing the subject from entering the study in the Investigator's opinion
Data sourced from ClinicalTrials.gov (NCT03003130). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.